Purpose: Neoadjuvant chemotherapy (NAC) frequently results in shrinkage of the primary tumor. It is not easy to perform breast-conserving surgery (BCS) after NAC, based on tumor extent alone. We identified the clinicopathological factors associated with positive margins on frozen or permanent sections in patients undergoing BCS after NAC. Methods: The records of 151 patients who had BCS after NAC between 2005 and 2010 were reviewed. All patients underwent subsequent imaging work-up including breast magnetic resonance imaging, ultrasound, and breast mammography at the midpoint and/or the end of NAC. Positive resection margins on frozen or permanent sections were considered to be due to the presence of either invasive carcinoma or in situ carcinoma. The relationship between the microscopic margin status and clinicopathological factors was analyzed when positive margins were detected. Results: Of 151 patients, 39 (25.8%) were diagnosed with a pathological complete response, while 135 patients (89.4%) had a negative margin on both frozen and permanent sections and 16 (10.6%) had a positive margin on frozen or permanent sections. Of the 16 patients, 14 finally obtained negative margins after additional excision and two (1.3%) had positive margins due to in situ carcinoma. Multivariate analysis revealed that clinical multifocality after NAC (p= 0.006), and hormonal receptor (HR) positivity (p= 0.028) were significantly associated with positive margins on frozen or permanent sections, but were not associated with tumor size after NAC, specimen volume, or human epidermal growth factor receptor 2 positivity. Conclusion: We propose that HR positivity and clinical multifocality after NAC are predisposing factors for positive margins in patients undergoing BCS after NAC. It is necessary to obtain safe resection margins to avoid positive margins in these patients.
INTRODUCTION
Breast-conserving surgery (BCS) and radiation therapy are locoregional treatments that serve as alternatives to mastectomy for women with early-stage breast cancer [1] . Neoadjuvant chemotherapy (NAC) has very attractive advantages for patients with advanced breast cancer. First, it is a unique opportunity to evaluate treatment response in vivo. Second, reducing the tumor size increases the likelihood of successful BCS [2, 3] . However, several authors have reported high local recurrence rates in patients who undergo BCS after NAC [4, 5] ; therefore, some breast oncologic surgeons are reluctant to advocate BCS after NAC.
There is ongoing controversy regarding the optimal safety margins for patients undergoing BCS, with and without NAC [6, 7] . The Society of Surgical Oncology/American Society of Radiation Oncology consensus panel at the 15th annual meeting of the American Society of Breast Surgeons concluded that ''no ink on the tumor'' constituted an adequate surgical margin for BCS in patients with invasive breast cancers [8] . However, the acceptable safety margin may differ depending on whether the patient is undergoing conventional BCS or BCS after NAC. A reduction in tumor size makes identification of the original tumor size difficult, particularly when the treatment response is robust. Moreover, large tumors at presentation may not be uniformly
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Obtaining Negative Margins in Breast-Conserving Surgery after Neoadjuvant Chemotherapy 9 destroyed by chemotherapy; thus, a negative resection margin is not guaranteed [9, 10] . Nevertheless, the goals for the breast oncologic surgeon should be complete cancer extirpation with acceptable safety margins and an optimal cosmetic result. Positive margins in women who have received conventional BCS lead to increased ipsilateral breast tumor reappearance rates [11, 12] . Herein, we identified the clinicopathological factors associated with positive margins on frozen or permanent sections in patients undergoing BCS after NAC. In addition, we identified an effective surgical strategy to avoid positive margins and to achieve good cosmetic results in these patients.
METHODS
Our Institutional Review Board (IRB) approved this retrospective study (IRB approval number: SMC-2014-10-098). 
Definitions of variables
The clinical neoadjuvant response following NAC was defined by breast MRI findings based on the revised Response Evaluation Crite-ria in Solid Tumors (RECIST) guidelines version 1.1 [14] . A clinical complete response (cCR) was defined as no evidence of malignancy in the breast by using MRI. All other clinical responses, i.e., a partial response, stable disease, and progressive disease were defined as non-cCR. A pathological complete response (pCR) was defined as no evidence of malignancy in the breast in the permanent pathological report. The clinical tumor size after NAC, including that of invasive and in situ carcinomas, was estimated along the long axis of the malignant lesion by breast MRI, sonography, and mammography. Clinical multifocality was defined as evidence of a multifocal lesion in the breast by using MRI, sonography, and mammography after NAC. A breast lesion was regarded as multifocal if more than one well-demarcated invasive or in situ tumor was detected with a mass or nonmass lesion, such as microcalcifications on mammography or other suspicious lesions on sonography or breast MRI, separated from each other, regardless of the distance between the lesions.
The BCS specimen volume was estimated by the half-ellipsoid-volume method according to the details in the pathology report (4π abc/6; where a, b, and c are ellipsoid semi-axes) [15] . Other NAC regimens included that of the NeoSphere trial [16] , which involved trastuzumab and/or pertuzumab, plus docetaxel or trastuzumab and pertuzumab without docetaxel; doxorubicin/cyclophosphamide plus ixabepilone; the NeoALTTO trial [17] lapatinib-containing regimen; and neo-PGH trial comprising paclitaxel, gemcitabine plus trastuzumab; the HannaH study [18] regimen, which comprised docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide concurrently with trastuzumab.
Neoadjuvant chemotherapy regimens
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Adjuvant therapy
Adjuvant radiation therapy was delivered to the whole breast at a total dose of 50 Gy in 25 fractions. A tangential technique with 4-or
6-MV photon beams generated by a linear accelerator (Varian Medical
Systems, Palo Alto, USA) was used for whole breast irradiation. The primary tumor bed was boosted according to the resection margin status and primary tumor size. The boost dose was 9-12 Gy with a daily dose of 2-3.5 Gy. An electron beam was used for the primary tumor bed boost. Irradiation of the supraclavicular fossa was undertaken according to clinical and pathological N stage. Adjuvant hormone therapy and HER2-targeted therapy were administered based on the IHC results.
Surgical technique and assessment of margin status
We attempted en bloc resection if there was a suspicion of invasive or in situ carcinoma. The surgical margin was deemed to be 1 cm from the tumor by preoperative modalities. Preoperative localization of a nonpalpable or a multiformly destroyed mass after NAC was per- 
Statistical methods
The clinicopathological parameters associated with positive margins on frozen or permanent sections were analyzed by using the Wilcoxon two-sample test and the chi-square test. A p-value < 0.05 was considered statistically significant. A logistic regression model with Firth's penalized maximum likelihood estimation method was used.
Preoperative variables with p-values < 0.05 were selected by univariate analysis to determine predisposing factors for positive margins.
Clinical T-stage at diagnosis representing the extent of the primary tumor, clinical tumor size after NAC, preoperative localization, and specimen volume were clinically important factors required to obtain negative margins, and were included in the logistic regression model.
Hazard ratios and 95% confidence intervals were calculated. The statistical analysis was executed using SAS version 9.3 (SAS Institute, Cary, USA) and R 2.13.2 (Vienna, Austria; http://www.R-project.org).
RESULTS
In total, 151 patients were reviewed in this analysis. The patient characteristics are shown in Table 1 The clinicopathological characteristics are shown in Table 2 . According to the RECIST guidelines [14] , a cCR was predicted for 29 pa- (Table 3 ). We selected the clinically important preoperative variables required to obtain negative margins and included them in a logistic regression model. Multivariate analyses revealed that clinical multifocality after NAC (p = 0.006) and HR positivity (p = 0.028) were independent risk factors for positive frozen-or permanent-section margins, but were not associated with clinical T-stage at diagnosis, tumor size after NAC, preoperative localization, specimen volume, or HER2-receptor positivity (Table 4 ).
DISCUSSION
Over the past decade, NAC has been increasingly used for patients with operable breast cancer to reduce large tumors to a size eligible for BCS. Clinical trials and meta-analyses have established equivalent overall survival rates for pre-and postoperative chemotherapy; however, the question of long-term local control following BCS after NAC remains controversial [2, 3, 19] . Although some studies have reported locoregional recurrence (LRR) rates following NAC and BCS as high as 26%, more recently reported rates are 7% to 16% [2, 20] . A recent analysis of a single institutional experience with BCS demonstrated that LRR rates are low for patients treated either with initial surgery (6% at 10 years) or NAC (10% at 10 years), and the initial treatment modality had no significant impact on LRR-free survival rates after 
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adjusting for the clinical stage at presentation [21] .
No uniform definition of surgical margin status has been established. A general consensus was reached by a series of published studies indicating that a surgical margin is positive if cancer cells are immediately at the edge of the resection on an inked histology section, according to investigators from the National Surgical Adjuvant Breast and Bowel Project [22] . In contrast, 1 mm is currently designated as the minimal distance for a positive surgical margin according to the European Institute of Oncology [23] . A huge population meta-analysis (LRR in 1,506 of 28,162) reported that a negative margin reduces LRR in patients with early-stage breast cancer and BCS. However, increasing the distance used to define a negative margin did not result in a significantly reduced LR [7] .
Acceptable safety margins in patients with BCS after NAC are even more controversial [6] , as they differ from those for patients undergoing conventional BCS. Large tumors on presentation may not be uniformly destroyed by chemotherapy; hence, a negative-resection margin is not guaranteed. Furthermore, determining original tumor size is difficult, particularly when a major response to NAC is obtained [9, 10] . Nevertheless, most breast oncologic surgeons aim to obtain negative-resection margins for local control and tend to excise large volumes of tissue during BCS after NAC [15] .
Reoperation after BCS because of positive margins is common and re-excision rates vary widely, but are generally 15% to 40% [24, 25] . Two main factors must be considered to reduce the reoperation rate following detection of positive margins. First, it is essential to determine the extent of resection, particularly in patients who have a major response to NAC and MRI is an established tool to evaluate this response. Despite the superior accuracy of MRI compared with other modalities (breast mammography and ultrasound), residual tumor extent can be over-or underestimated [26] . Several reports have suggested that the diagnostic reliability of conventional MRI may vary according to cancer subtype; lower accuracy was associated with the luminal subtype rather than the triple-negative and HER2-positive phenotypes [27, 28] . In our study, HR positivity was a preoperative predisposing factor for positive frozen-or permanent-section margins. Second, evaluation of intraoperative strategies that could reduce positive margins would be useful, including localization by intraoperative ultrasound, radio-guided localization, specimen radiographs, or intraoperative margin assessment such as gross evaluation only or microscopic margin evaluation including imprint cytology or frozensection analysis. In our study, we performed appropriate localization, specimen radiography, and frozen-section biopsies, and found that the latter had a high specificity (98.5%). We found a low positive-margin rate on permanent sections (4/151, 2.7%).
The median follow-up after BCS was 49.4 months (range, 2.3-110.4 months). Only one patient developed local recurrence, four had regional recurrence, and 21 had distant recurrence. Only one local recurrence was detected by imaging follow-up 37.5 months after BCS.
We surmise that this relatively low LRR was due to the use of appropriate adjuvant therapies such as radiation, hormonal, and HER2-targeted therapies. In our study, almost all patients underwent radiation therapy, and the primary tumor bed was boosted in 83.1% (123/148).
Some reports indicate that radiation therapy offers improved local control. Huang et al. [29] found that comprehensive radiation benefits both local control and survival in patients presenting with clinical T4 tumors or stage III-IV disease, in addition to those with four or more positive nodes in the NAC setting. Bartelink et al. [30] reported that boost radiation of the tumor bed led to improved local control, but no difference in survival after a median follow-up period of 10.8 years.
Our study had several limitations. First, we used a number of NAC regimens due to differences in the NAC response; there were eight NAC regimens but four inclusive groups were defined, largely because some of the NAC regimen groups had few patients. Nevertheless, we focused mainly on negative margins in patients who underwent BCS after NAC and evaluated their clinical response. Second, a positive frozen-section margin was assumed to indicate a positive-margin status. We had very few positive permanent-section margins (4/151, 2.7%) because we always performed a frozen-section biopsy, and additional resection was performed to obtain negative frozen-section margins intraoperatively. If we did not perform frozen-section biopsies, positive permanent-section margins would have been considered.
Strikingly, 49% of the audience at the 15th Annual Meeting of the American Society of Breast Surgeons were not using any intraoperative margin-assessment method [8] . We consider using a method such as frozen-section biopsies to be extremely important. Third, this was a retrospective study and the sample size was not very large. However, our median follow-up period was 49.4 months, which is longer than that of previous studies.
Despite these limitations, our results have important clinical impli-
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cations. First, HR positivity and clinical multifocality after NAC were predisposing factors for positive margins in patients with BCS after NAC. Second, despite the short-term follow up, there were only four cases of LRR, suggesting that negative margins at the margin cut and appropriate adjuvant therapy are necessary for patients undergoing BCS after NAC.
In conclusion, our retrospective study revealed that HR positivity and clinical multifocality were significantly associated with positive margins. We encourage surgeons to obtain safe resection margins to avoid positive margins in patients with these clinicopathological factors.
